Regulatory & Legal

Beyond the lavish anniversary party, the Chinese spirits giant is leveraging a century of history in a sophisticated bid to conquer the Western market.

A new point-of-care PCR test is moving closer to reality in India, promising to revolutionize the fight against tuberculosis and cervical cancer.

The biotech is advancing a promising myelofibrosis therapy while developing a next-gen 'super drug,' a dual strategy signaling significant growth.

After key legal setbacks, Pason Systems settles its IP litigation. We decode what this confidential agreement means for investors and future innovation.

As AI-driven deepfakes surge, a 5-year-old film reveals why media literacy is the most critical, yet overlooked, infrastructure for our smart cities.

A new investment narrative targets 'essential' sectors. A deep dive reveals a complex mix of real strategy, verifiable progress, and pure promotion.

A massive natural gas pipeline aims to fuel Nevada's tech boom. But does this $1.7 billion bet on fossil fuels conflict with the state's green energy future?

John Crowley, who fought to save his own children, will now shape the future of medicine as he headlines the landmark 2026 MDA conference.

One junior miner in Québec is rewriting the script by owning its mill, a strategic move that de-risks the path from exploration to cash flow.

A simple phone line delivers messages from resilient kids. We decode the powerful science showing how these wishes improve health and drive recovery.

Quantum computers will soon break today's encryption. A new security standard is here, but are automakers moving fast enough to prevent a systemic failure?

Fate Therapeutics' latest data suggests its iPSC-derived CAR-T could revolutionize lupus care, moving cell therapy beyond cancer and into the mainstream.

A key regulatory step for Hadron Energy's micro-reactor, backed by a unique SPAC model, signals a high-stakes bet on the future of U.S. energy.

In a stunning strategic shift, Transcontinental sells its largest division to ProAmpac, rewarding shareholders and refocusing on its printing roots.

Vyome's positive Phase 2 data targets a silent suffering in cancer care. This analysis explores its strategy to dominate a potential $1 billion market.

SAB Biotherapeutics' novel T1D therapy shows promise with a unique safety profile, challenging the status quo and offering new hope for patients.

A top care provider changes hands not by choice, but by debt. What does Colisée's fate reveal about the risks of private equity in social care?

The future of boating isn't just in showrooms. It's in garages where DIYers are driving a quiet, clean-energy revolution on the water. Here's how.

New data reveals Syndax's Revuforj is a game-changer for leukemia, sparking a battle for market dominance in targeted cancer therapy.

How does a MedTech firm win 'Top Workplace' twice? Echosens proves that a mission-driven culture is the ultimate catalyst for innovation and market leadership.